Apolipoprotein C3: form begets function
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Increased circulating levels of apolipoprotein C3 (APOC3) predict cardiovascular disease (CVD) risk in humans, and APOC3 promotes atherosclerosis in mouse models. APOC3's mechanism of action is due in large part to its ability to slow the clearance of triglyceride-rich lipoproteins (TRLs) and their remnants when APOC3 is carried by these lipoproteins. However, different pools and forms of APOC3 exert distinct biological effects or associations with atherogenic processes. Thus, lipid-free APOC3 induces inflammasome activation in monocytes whereas lipid particle-bound APOC3 does not. APOC3-enriched LDL binds better to the vascular glycosaminoglycan biglycan than does LDL depleted of APOC3. Patterns of APOC3 glycoforms predict CVD risk differently. The function of APOC3 bound to HDL is largely unknown. There is still much to learn about the mechanisms of action of different forms and pools of APOC3 in atherosclerosis and CVD, and whether APOC3 inhibition would prevent CVD risk in patients on LDL-cholesterol lowering medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“First, genetic evidence based on loss-of-function variants of APOC3 and Mendelian randomization studies strongly support a causative role for APOC3 in increasing plasma triglycerides and CVD risk (1 – 4).”
BackgroundTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 13×
“In the above study (4), remnant cholesterol was estimated by subtracting LDL-cholesterol and HDL-cholesterol from total cholesterol, and in a subcohort was measured directly.”
BackgroundInfluentialVolanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528 · cited 2×
“APOC3 inhibition should also be evaluated in cohorts including Asian Indians because APOC3 loss-of-function variants appear to be less effective in lipid-lowering in Asian Indians than in people of European descent (86).”
BackgroundApolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation
Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S. J., Schmit, D., Kramann, R., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0548-1 · Cited by 280 · cited 4×
“In addition to the release of IL-1 β as a result of inflammasome activation, delipidated APOC3 induces expression and secretion of other inflammatory and pro-coagulatory mediators in human monocytes, including TNF-α , IL-6, and tissue factor (65, 68).”
BackgroundInfluentialApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274 · cited 3×
“This conclusion is backed up by a mouse study, in which APOC3 silencing lowered both TRL triglyceride and cholesterol in LPL-deficient mice (44).”
BackgroundAlexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease
Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E. (2020) · Diabetes · doi:10.2337/dbi19-0007 · Cited by 229 · cited 7×
“Remnant lipoprotein particles can be defined as postlipolytic partially triglyceride-depleted particles derived from chylomi-crons and very-low-density lipoprotein (VLDL) that are relatively enriched in cholesteryl esters and apolipoprotein E (APOE) (5).”
BackgroundMethodInfluentialSelf-citationMacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29154 · Cited by 216 · cited 2×
“Thus, hepatic heparan sulfate is a critical part of the mechanism of clearing both cholesterol-rich lipoprotein particles and triglyceride-containing lipoprotein particles, and this effect is accentuated in states in which LDL receptors are downregulated (55).”
BackgroundThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196 · cited 2×
“APOC3 has two mechanisms of action in triglyceride and cholesterol metabolism, both related to slower clearance of TRLs (16, 42).”
BackgroundBjörnson, E., Adiels, M., Taskinen, M.-R., Burgess, S., Rawshani, A., Borén, J., & Packard, C. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad337 · Cited by 183
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200322-jlr200 · Cited by 114 · cited 1×
“For example, APOC3-containing LDL and VLDL bind better to the vascular proteoglycan biglycan than lipoproteins depleted of APOC3, and this effect is mediated by APOB rather than by direct APOC3 binding to the proteoglycan (69, 70).”
BackgroundNavarese, E. P., Vine, D., Proctor, S., Grzelakowska, K., Berti, S., Kubica, J., & Raggi, P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319297 · Cited by 107
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Reyes-Soffer, G., Sztalryd, C., Horenstein, R. B., Holleran, S., Matveyenko, A., Thomas, T., Nandakumar, R., Ngai, C., Karmally, W., Ginsberg, H. N., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311476 · Cited by 97
Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes
on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3535-6 · Cited by 66 · cited 1×
“…both total APOC3 and APOC3 carried by APOB-lipoproteins with coronary heart disease in subjects with type 2 diabetes and median triglycerides in the normal range (19), whereas in another study, APOC3 levels associated negatively with CVD, despite a positive correlation with triglycerides (20).”
ResultApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093740 · Cited by 59 · cited 1×
“Research on mouse models has also shown that APOC3 can prevent tissue LPL action in vivo, at least when APOE, a ligand for LDLR and LRP1, is absent (45, 53).”
BackgroundRole of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55 · cited 1×
“Indeed, the secretion rate of APOC3 is associated with elevated TRLs in subjects with type 2 diabetes (24).”
Background
Cited by
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
Masson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
Gao, Y., Bai, Y., Mu, X., & Pang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736821 · Cited by 4
“…APOC3 and ANGPTL3 have demonstrated marked TG reductions and favorable effects on non–HDL-C, apoB, and very-low-density lipoprotein cholesterol (VLDL-C) across phase I–III clinical trials (Gaudet et al., 2024; Huynh, 2024; Ray et al., 2025; Bornfeldt, 2024; Schwabe et al., 2020; Lim, 2024).”
Metadata
- Authors
- Bornfeldt, K. E.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 65
- Issue
- 1
- Pages
- 100475
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W4388662938
- Cited by
- 45
- References
- 20
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.